NCT01076439
Withdrawn
Phase 4
A Pilot Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo Nasal Spray in Reducing Nasal Allergic Symptoms Following Ragweed Exposure in the Allergen BioCube (ABC)
ORA, Inc.0 sitesFebruary 26, 2010
ConditionsAllergic Rhinitis
Overview
- Phase
- Phase 4
- Intervention
- Olopatadine Nasal Spray
- Conditions
- Allergic Rhinitis
- Sponsor
- ORA, Inc.
- Primary Endpoint
- Nasal Signs and Symptoms (TNSS)
- Status
- Withdrawn
- Last Updated
- 14 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the onset of action of fluticasone furoate nasal spray compared to olopatadine nasal spray and placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube (ABC) after single dose administration and six consecutive days of treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •provide written informed consent and signed HIPAA form;
- •be able and willing to follow all instructions and attend the study visits;
- •if female and of childbearing potential, be not pregnant, nursing or planning a pregnancy, be willing to submit a pregnancy test at visit 1 and at exit visit, and to use adequate method of birth control
- •have a positive history of seasonal allergic rhinitis to ragweed;
- •have a positive skin test reaction to ragweed of within the past 24 months;
- •manifest sufficient allergic rhinitis symptoms during ragweed exposure in the ABC
Exclusion Criteria
- •manifest symptoms of clinically active allergic rhinitis at the start of Visit 1 or Visit 2;
- •known intolerance or allergy to antihistamines or corticosteroids;
- •have a compromised lung function at Visit 1;
- •have significant nasal anatomical deformities or any condition that does not allow subject to breathe through the nose (includes, but is not limited to: septal deviation, septal perforations, nasal polyps, rhinitis medicamentosa)
- •have had any nasal surgical intervention in the past;
- •have planned surgery (nasal, ocular or systemic) during the trial period or within 30 days thereafter;
- •use disallowed medications (topical, topical ophthalmic, systemic and/or injectable treatments and all anti-allergy therapies including prescription, over the counter or homeopathy, and over the counter sleeping aids) during the study or appropriate pre-study washout period
Arms & Interventions
Olopatadine Nasal Spray (Patanase)
Intervention: Olopatadine Nasal Spray
Fluticasone Furoate Nasal Spray (Veramyst)
Intervention: Fluticasone Furoate Nasal Spray
Saline Nasal Spray (Placebo)
Intervention: Saline Nasal Spray
Outcomes
Primary Outcomes
Nasal Signs and Symptoms (TNSS)
Time Frame: Evaluated by the subject pre-ABC exposure, every 15 minutes during all ragweed exposures in the ABC, and post-ABC exposure
TNSS (0-12 unit scale) is defined as the sum of the four nasal symptom scores recorded for nasal itching, sneezing, rhinorrhea and nasal congestion.
Secondary Outcomes
- Peak Expiratory Flow Rate (PEFR)(Measured pre-ABC exposure, every 30 minutes during all ragweed exposures in the ABC, and post-ABC exposure)
- Peak Nasal Inspiratory Flow (PNIF)(Measured pre-ABC exposure, every 30 minutes during all ragweed exposures in the ABC, and post-ABC exposure)
- Headaches(Evaluated by the subject pre-ABC exposure, every 30 minutes during all ragweed exposures in the ABC, and post-ABC exposure)
Similar Trials
Completed
Phase 4
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to PlaceboAllergic RhinitisAllergic ConjunctivitisNCT01439815ORA, Inc.22
Completed
Phase 2
Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute RhinosinusitisSinusitis, AcuteNCT01018030GlaxoSmithKline741
Completed
Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic RhinitisRhinitis, Allergic, PerennialAllergic RhinitisNCT01231464GlaxoSmithKline365
Completed
Phase 4
Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BIDAsthmaCandidiasis, OralVoice DisordersNCT00235053Allergy & Asthma Medical Group & Research Center13
Completed
Phase 1
Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)Pulmonary Disease, Chronic ObstructiveNCT02441114Seoul National University Hospital10